Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/22/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
02/22/2023* -- Results Q4 2022 -- -1.34 --
10/27/2022 16:30 EST Earnings Call Q3 2022 -- -- --
10/27/2022 -- Results Q3 2022 -1.53 -1.26 -21.15%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -2.13 -1.48 -43.60%
05/03/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/03/2022 -- Results Q1 2022 -1.78 -1.66 -7.36%
*Estimated Date/Time

Earnings

Next Report Date 02/22/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 10/27/2022
Beat/Miss Upgrade
Return Since -5.67%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
URL https://www.ptcbio.com
Investor Relations URL https://ir.ptcbio.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 22, 2023 (est.)
Last Earnings Release Oct. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-37.42%
-66.33%
52.89%
105.8%
39.95%
27.07%
-34.74%
5.60%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
--
--
--
--
-42.62%
268.2%
-48.82%
-68.32%
--
--
--
--
--
--
--
89.23%
-10.22%
7.71%
52.37%
-24.10%
80.56%
84.85%
23.02%
-59.19%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-84.33%
As of December 02, 2022.

Profile

Edit
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
URL https://www.ptcbio.com
Investor Relations URL https://ir.ptcbio.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 22, 2023 (est.)
Last Earnings Release Oct. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
JSJCX 13.03M USD 3.15%
FRBRX 25.26M USD 3.03%
IBRN 154310.0 USD 3.00%
BBP 395393.0 USD 2.34%
FIJYX 39.59M USD 2.31%
FBIOX 113.85M USD 2.24%
TMFS 1.379M USD 2.02%
SBIO 1.830M USD 1.71%
LCGRX 27.31M USD 1.37%
FPHAX 7.917M USD 1.02%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter PTCT Tweets